Raj K. Maturi, MD Adam R. Glassman, MS Kristin Josic, PHD Carl W. Baker, MD Adam T. Gerstenblith, MD Lee M. Jampol, MD Annal Meleth, MD Daniel F. Martin, MD Michele Melia, ScM Omar S. Punjabi, MD Soraya Rofagha, MD, MPH Hani Salehi-Had, MD Cynthia R. Stockdale, MSPH Jennifer K. Sun, MD, MPH DRCR Retina Network David Browning John Bradley Allen Andrew N. Antoszyk Amanda H. Wilson Brittany A Murphy Christina J. Fleming Courtney Mahr Angela K. Price Justin Clark Sarah A. Ennis Sherry L. Fredenberg Taylor S. Jones Monica D. Nayar Kayla A Bratcher Kaitlin T. McShea Erica Breglio Christina Mutch Angella K. Gentile Carol A Shore Donna McClain Loraine M. Clark Lisa A. Jackson Lynn Watson Michael D. McOwen Tracy A. Ross Uma M. Balasubramaniam Shannon Stobbe Yvonne Ramirez Sara Ahmed Stephanie Ramirez Undariya Boldbaatar Valeria Quintero Evelyn Ceja Scott F. Lee Jesus Cortes Katie Tran Mary Ma Mailan Tran Nikki Nguyen Lily Castillo Janet Reyes Karen Gasperian Robert E. Parnes April L. Stockman Jennifer Shirey Kylie Stambaugh Lora Glaspell Leslie Toomey Angie Goldizen Charles C. Wykoff David M. Brown Amy C. Schefler Ankoor R. Shah Eric Chen James C. Major Jr. Ocular Adverse Events Occurring in Non-Study Eyes After the First Non-Study Eye Aflibercept Injection by Treatment Group Through 2 Years Ocular Adverse Events Occurring in Study Eyes by Treatment Group Through 2 YearsĮTable 12. Systemic Adverse Events by Treatment Group Through 2 YearsĮTable 11. New and Worsening Retinal Detachments by Treatment GroupĮTable 10. Retinal Thickening by Treatment Group, Adjusted for Baseline Lens Status: Secondary and Exploratory OutcomesĮTable 9. Proliferative Diabetic Retinopathy Complications by Treatment Group, Adjusted for Baseline Lens Status: Secondary OutcomesĮTable 8. Additional Secondary Visual Acuity Outcomes by Treatment GroupĮTable 7. Exploratory Visual Acuity Outcomes by Treatment GroupĮTable 6. Subgroup Analyses of Average Visual Acuity Score Over 24 Weeks by Treatment Group, Adjusted for Baseline Visual Acuity and Lens StatusĮTable 5. Sensitivity Analyses of Average Visual Acuity Score Over 24 Weeks by Treatment Group, Adjusted for Baseline Visual Acuity and Lens StatusĮTable 4. Initial Vitrectomy in the Initial Vitrectomy GroupĮTable 3. Indications for Vitrectomy During Follow-up by Treatment GroupĮTable 2. Time to First Treatment for Center-Involved Diabetic Macular Edema by Treatment Group: Exploratory OutcomeĮTable 1. Mean Visual Acuity Letter Score Through 2 Years by Treatment GroupĮFigure 3. Time to First Vitrectomy in the Initial Aflibercept Group: Secondary OutcomeĮFigure 2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |